Michael Lee, MD
Cardiovascular Disease · Derby, CTNPI 1730124793
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,361 of the $11,360 with a category attached, or 73.6%. 18 manufacturers reported payments, led by Teleflex LLC at 58.1% of the total. Reporting peaked in 2022 at $7,097 and has fallen 83.1% since, to $1,201 in 2025.
Across 43 payments — averaging $264.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$7K
- Medtronic$1K
- BD$1K
- W. L. Gore & Associates, Inc.$375
- Cipla USA Inc.$368
- Abiomed$261
- plus $1K from 12 others
What the payments were for
- Consulting fees$8,36174%
- Speaking & faculty fees$8037%
- Travel & lodging$9338%
- Food & beverage$1,26411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 8 | $6,603 |
| Medtronic | 8 | $1,350 |
| BD | 3 | $1,046 |
| W. L. Gore & Associates, Inc. | 1 | $375 |
| Cipla USA Inc. | 1 | $368 |
| Abiomed | 2 | $261 |
| Penumbra, Inc. | 1 | $235 |
| Analog Devices Inc. | 1 | $225 |
| Vifor (international) Ltd. | 1 | $200 |
| Cathworks, Inc. | 1 | $133 |
| Johnson & Johnson | 1 | $123 |
| Philips North America LLC | 1 | $114 |
| Baxter Healthcare | 2 | $93 |
| Shockwave Medical, Inc | 1 | $83 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $52 |
| Novartis | 3 | $45 |
| Abbott | 2 | $39 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MANTA$6,398
- Product in Development$375
- Impella$261
- Indigo System$235
- FFRangio System$133
- Erleada$123
- AKEEGA$123
- IGT D Coronary$114
How this compares
$11,360 in reported general payments places this provider in the 85th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 25 | $193 |
| Metoprolol Succinate | 19 | $170 |
| Losartan Potassium | 17 | $145 |
| Amlodipine Besylate | 27 | $126 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Derby
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
- Antonio FernandezHartford$113K
- Paul ThompsonHartford$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.